Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study.

Area of Science:

• Neuroimmunology
• Clinical Neurology
• Pharmacology

Background:

• Multiple Sclerosis (MS) encompasses relapsing-remitting (RRMS) and primary progressive (PPMS) forms.
• Ocrelizumab is a targeted therapy for MS, but its comparative effectiveness in real-world settings requires further investigation.

Purpose of the Study:

• To compare the clinical and radiological effectiveness of ocrelizumab in PPMS versus RRMS.
• To assess the tolerability and adverse events associated with ocrelizumab treatment.

Main Methods:

• Retrospective observational cohort study.
• Inclusion of patients with PPMS and RRMS treated with ocrelizumab for at least one year.
• Comparison of clinical and MRI data, including No Evidence of Disease Activity (NEDA) and radiological activity.

Main Results:

• Ocrelizumab significantly reduced relapses and MRI activity in both RRMS and PPMS patients.
• A notable reduction in radiological activity was observed within the first year, with complete reduction by the second year.
• While progression was slowed, this effect was more sustained in RRMS patients compared to PPMS patients, who showed increased progression in the second year.

Conclusions:

• Ocrelizumab demonstrates significant efficacy in managing MS by reducing disease activity.
• The drug is generally well-tolerated, with infusion-related reactions and infections being the most common adverse events.
• Long-term effectiveness may differ between PPMS and RRMS, necessitating continued monitoring.